Recognition benchmarks disability workplace inclusion against other companies

Discover the latest trends and emerging strategies to manage rising medical benefit specialty drug spend.

From cutting-edge system solutions to powerful stakeholder partnerships, the Medicaid Enterprise Systems Conference delivered key insights and connections that will shape health care modernization...

Jared Scripture, health outcomes scientist, shares more about the study “Leveraging Publicly Available SDOH Measures to Segment Members and Quantify Differences in Diabetic Medication Adherence: A...

Jessica Johnson, clinical consultant at Prime, shares some tips to stay safe

AMCP Nexus offers opportunity to nurture next generation of managed care leaders

Members on cancer care journey laud Prime’s integrated clinic-to-pharmacy experience

Three studies to be recognized with awards

Prime leaders discuss rebates, reporting and other state issues at hybrid conference in Chicago.

Experts in Medicaid pharmacy delivery engage in timely discussion of states’ access and cost challenges and offer Prime’s solutions to fill resource gaps and improve health outcomes for people...

Job-seeking platform recognizes Prime’s leadership in championing flexible work

Joseph Leach, M.D., senior vice president and chief medical officer at Prime Therapeutics/Magellan Rx Management, shares more about the RTBC electronic prescription decision support tool

Prime’s IntegratedRx® – Cystic Fibrosis product earns 94% member satisfaction rate

Prime Therapeutics residents, Almina Gomez and Kathryn Makay, shared their research and experiences at annual managed care pharmacy event 

Reprinted with AIS Health permission from the November 2024 issue of Radar on Specialty Pharmacy

Prime Therapeutics offers holistic and data-driven solutions to manage drug costs and simplify the patient experience for those with hemophilia and other blood disorders

Magellan Rx first to innovate with Medicaid VBC solutions for states grappling with the high cost of novel cell and gene therapies

Prime celebrates 25th anniversary, and Magellan Rx celebrates 10th anniversary

In late 2023, the FDA approved a new treatment regimen for urothelial cancer that represents a “paradigm change,” according to one industry expert

Nicole Grevenitz, director of clinical account services, shares more from the research study “Promoting Health Equity Through Enhanced, Personalized Digital Outreach.”